Cover Image
市場調查報告書

原發性矮小症(Idiopathic Short Stature):開發平台分析

Idiopathic Short Stature - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 302494
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
原發性矮小症(Idiopathic Short Stature):開發平台分析 Idiopathic Short Stature - Pipeline Review, H2 2015
出版日期: 2015年08月12日 內容資訊: 英文 36 Pages
簡介

所謂原發性矮小症(Idiopathic Short Stature)是指身高極端的矮,原因不明。症狀包含體重減少/增加,營養不良,食慾不振,慢性腹痛·腹瀉,持續性發熱,慢性頭痛等。

本報告提供原發性矮小症(Idiopathic Short Stature)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

原發性矮小症(Idiopathic Short Stature)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • JCR Pharmaceuticals Co., Ltd.
  • LG Life Sciences, Ltd.
  • Myungmoon pharmaceutical Co.,Ltd.
  • Braasch Biotech LLC
  • Bolder Biotechnology, Inc.
  • Dong-A Socio Holdings Co Ltd

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BBT-031
  • MMP-0201
  • somatropin
  • somatropin SR
  • 面向生長激素缺乏症疫苗

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7042IDB

Summary

Global Markets Direct's, 'Idiopathic Short Stature - Pipeline Review, H2 2015', provides an overview of the Idiopathic Short Stature's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Short Stature, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Short Stature and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Short Stature
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Idiopathic Short Stature and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Idiopathic Short Stature products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Idiopathic Short Stature pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Short Stature
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Idiopathic Short Stature pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Idiopathic Short Stature Overview
  • Therapeutics Development
    • Pipeline Products for Idiopathic Short Stature - Overview
    • Pipeline Products for Idiopathic Short Stature - Comparative Analysis
  • Idiopathic Short Stature - Therapeutics under Development by Companies
  • Idiopathic Short Stature - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Idiopathic Short Stature - Products under Development by Companies
  • Idiopathic Short Stature - Companies Involved in Therapeutics Development
    • Bolder Biotechnology, Inc.
    • Braasch Biotech LLC
    • Dong-A Socio Group
    • LG Life Sciences, Ltd.
    • Myungmoon pharmaceutical Co.,Ltd.
  • Idiopathic Short Stature - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BBT-031 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MMP-0201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Growth Hormone Deficiencies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Idiopathic Short Stature - Recent Pipeline Updates
  • Idiopathic Short Stature - Dormant Projects
  • Idiopathic Short Stature - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic Short Stature, H2 2015
  • Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Idiopathic Short Stature - Pipeline by Bolder Biotechnology, Inc., H2 2015
  • Idiopathic Short Stature - Pipeline by Braasch Biotech LLC, H2 2015
  • Idiopathic Short Stature - Pipeline by Dong-A Socio Group, H2 2015
  • Idiopathic Short Stature - Pipeline by LG Life Sciences, Ltd., H2 2015
  • Idiopathic Short Stature - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Idiopathic Short Stature Therapeutics - Recent Pipeline Updates, H2 2015
  • Idiopathic Short Stature - Dormant Projects, H2 2015
  • Idiopathic Short Stature - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Idiopathic Short Stature, H2 2015
  • Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top